MMP-9
MMP-9 Molecule Information
Name:Matrix metalloproteinase 9
Target Synonym:92 kDa gelatinase;Gelatinase B;GELB;82 kDa matrix metalloproteinase-9;Matrix metalloproteinase-9;92 kDa type IV collagenase;CLG4B;MMP9;67 kDa matrix metalloproteinase-9;MMP-9
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:15
Lastest Research Phase:NDA Filing
MMP-9 Molecule Synonym Name
MMP9,CLG4B,GELB,MANDP2,Gelatinase B
MMP-9 Molecule Background
Matrix metallopeptidase 9 (MMP-9) is also known as 92 kDa type IV collagenase, 92 kDa gelatinase or gelatinase B (GELB), CLG4B, is secreted from neutrophils, macrophages, and a number of transformed cells, and is the most complex family member in terms of domain structure and regulation of its activity. . Structurally, MMP9 maybe be divided into five distinct domains: a prodomain which is cleaved upon activation, a gelatinbinding domain consisting of three contiguous fibronectin type II units, a catalytic domain containing the zinc binding site, a prolinerich linker region, and a carboxyl terminal hemopexinlike domain. This enzyme degrades various substrates including gelatin, collagen types IV and V, and elastin. MMP9 is involved in a variety of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis, and be regarded as a potential therapeutic target.
MMP-9 References
MMP-9 Public Drug Information
Name |
Research Code |
Research Phase |
Company |
First Brand Name |
First Approved Country |
First Indication |
First Approved Company |
First Approved Date |
Indications |
Clinical Trials |
Abametapir |
BRN-0123183; DFD-11; HA-44; Ha44 Gel |
Approved |
Hatchtech |
XEGLYZE |
fda |
|
DR REDDYS LABS SA |
2020-07-24 |
Pediculosis |
Details
|
MMP-9 Clinical Drug Information
Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
AQU-005 |
AQU-005; NMAQU-005; NM-AQU-005 |
Phase Ⅰ |
Aquilus Pharmaceuticals, NeuroMax |
Neuropathic pain |
Details
|
RBx-10017609 |
|
Phase Ⅱ |
Sun Pharmaceutical, GlaxoSmithKline |
Chronic obstructive pulmonary disease (COPD) |
Details
|
ABT-518 |
ABT 518 |
Phase Ⅰ |
Abbvie |
Solid tumours |
Details
|
SD-7300 |
|
Phase Ⅰ |
Pfizer |
Solid tumours |
Details
|
PG-116800 |
PG-116800; PG-530742; PGE-7113313,PG116800; PG530742; PGE7113313,PG 116800; PG 530742; PGE 7113313 |
Phase Ⅱ |
Procter & Gamble |
Osteoarthritis (OA), Heart failure, Myocardial infarction (MI) |
Details
|
Andecaliximab |
GS-5745 |
Phase Ⅲ |
Gilead |
Gastric cancer |
Details
|
AZD-1236 |
AZD-1236 |
Phase Ⅱ |
AstraZeneca |
Chronic obstructive pulmonary disease (COPD) |
Details
|
Incyclinide |
CMT-3; COL-3; NSC-683551 |
Phase Ⅱ |
Galderma |
Acne, Rosacea |
Details
|
S-3304 |
S-3304 |
Phase Ⅱ |
Shionogi |
Solid tumours |
Details
|
Tanomastat |
BAY-12-9566 |
Phase Ⅲ |
Bayer |
Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Ovarian cancer, Pancreatic cancer |
Details
|
AE-941 |
AE-941; NSC-706456 |
Phase Ⅲ |
AEterna Zentaris, Ferrer, Pfizer, National Cancer Institute, Alcon |
Non small cell lung cancer (NSCLC), Renal carcinoma |
Details
|
RS-130830 |
RS-130830; CTS-1027; RO-1130830,RS130830,CTS1027,RO1130830 |
Phase Ⅱ |
Roche, Conatus Pharmaceutical |
Arthritis, HCV infection |
Details
|
CP-471358 |
CP-471358 |
Phase Ⅰ |
Pfizer |
Solid tumours |
Details
|
Rebimastat |
BMS-275291; D-2163 |
Phase Ⅲ |
Celltech, Bristol-Myers Squibb |
Non small cell lung cancer (NSCLC) |
Details
|